Domestic price forecast of trametinib in 2025: Will patient burden be reduced?

Trametinib/Megenin (Trametinib) is a highly selective MEK1/2 inhibitor, mainly used to treat patients with BRAF Advanced melanoma with V600E or V600K mutations, and in combination with the BRAF inhibitor dabrafenib to treat certain patients with non-small cell lung cancer (NSCLC) and thyroid cancer. This targeted therapy drug blocks tumor cell proliferation signaling by inhibiting the MEK kinase activity in the RAS-RAF-MEK-ERK signaling pathway, thereby inhibiting tumor growth and delaying disease progression. Its treatment concept is based on precision medicine, which requires the presence of a BRAF mutation in the patient before it can be implemented to avoid ineffective treatment.

Currently, the original drug of trametinib has been launched in mainland China and has been included in the national medical insurance directory, and the cost of medication has dropped significantly. According to the existing drug pricing system, the reimbursement indications in its medical insurance catalog cover the use of dabrafenib in combination with BRAF mutation-positive unresectable or metastatic melanoma. Eligible patients will pay according to the Class B medical insurance reimbursement rate, and the actual cost burden will be greatly reduced. Currently, the mainstream specifications on the market are 2 mg 30 tablets and 0.5 mg 30 tablets. The price per box is about RMB 10,000. However, after medical insurance coverage, the patient’s out-of-pocket payment can be as low as a few thousand yuan or even less, depending on the city and medical insurance policy. It can be said that the inclusion of trametinib in medical insurance is a positive signal for advanced patients, improving drug accessibility and clinical treatment options.

In overseas markets, trametinib has original research and generic drugs on the market, and prices fluctuate greatly. However, when choosing overseas drugs, patients need to pay attention to the formality of the channels and drug quality assurance to avoid a decrease in efficacy or an increase in side effects due to improper use of drugs. Therefore, trametinib not only has significant advantages in efficacy, but the gradual improvement of its price and medical insurance support policies also allows patients to continue taking the drug and benefit from the clinical results of precise targeted therapy.

Reference materials:https://go.drugbank.com/drugs/DB08911